Google
CRIS Stock Price & Analysis — Curis Inc (Healthcare >> Biotechnology)
CRIS FAQ
What is CRIS's P/E ratio?
Curis Inc (CRIS) currently trades at a P/E ratio of 0.50.
What is CRIS's ROE?
Curis Inc reports a Return on Equity (ROE) of -166.56%.
What is CRIS's dividend yield?
Curis Inc offers a dividend yield of 0.00%.
What is CRIS's Quality Score?
Our AI rates CRIS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CRIS?
Our AI Timing Score for CRIS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CRIS belong to?
Curis Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CRIS AI Analysis Summary
Our AI summary for CRIS: Curis Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.50, ROE of -166.56%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.02
Price
0.06
(1.21%)
Day Change
|
|
|---|
CRIS, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.02 |
| PBV / Sector |
0.76 / 5.20
GREAT
|
| Earning Per Share | -10.99 |
| PE / Sector |
0.50 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
0.42 M
GREAT
|
| Average 1W Daily Value |
0.30 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
62% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:40 |
| Symbol | CRIS |
| Name | CURIS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 9.67 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building C, Lexington, MA, United States, 02421
Phone: 617 503 6500
Website: https://www.curis.com
Sector: Healthcare >> Biotechnology
Description: Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap